These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15926597)

  • 1. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 2. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Polypill in the prevention of cardiovascular disease.
    Wald DS; Wald NJ
    Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
    [No Abstract]   [Full Text] [Related]  

  • 4. [The polypill: not an effective strategy for reduction of cardiovascular disease].
    Westerweel PE; van Wijk JP; Verhaar MC
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1741. PubMed ID: 16114291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polypill holds promise for people with chronic disease.
    Wise J
    Bull World Health Organ; 2005 Dec; 83(12):885-7. PubMed ID: 16462975
    [No Abstract]   [Full Text] [Related]  

  • 7. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospects and possible pitfalls of a preventive Polypill: confessions of a health promotion convert.
    Green LW
    Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S4-8; discussion S9. PubMed ID: 16052194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single pill for prevention?
    Harv Heart Lett; 2009 Jul; 19(11):6. PubMed ID: 19927382
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chemopreventive agents in colorectal cancer].
    Benamouzig R; Chaussade S
    Rev Prat; 2003 Dec; 53(20):2213-4. PubMed ID: 15018072
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the current medical and economic times dictate the need for the "polypill"?
    Rifai L; Khan BV
    J Clin Hypertens (Greenwich); 2009 Dec; 11(12):775-6. PubMed ID: 20021541
    [No Abstract]   [Full Text] [Related]  

  • 13. Polypill: Can its Potential Enhancement of Efficacy Trigger New Interest?
    Chao J; Bansilal S
    Glob Heart; 2016 Dec; 11(4):469-472. PubMed ID: 27938845
    [No Abstract]   [Full Text] [Related]  

  • 14. Requirement of pharmacological treatment for primary prevention of cardiovascular disease in asymptomatic office-executives in north-India.
    Kasliwal RR; Bansal M; Mehrotra R; Agrawal V; Shrivastava S
    Indian Heart J; 2010; 62(4):324-9. PubMed ID: 21280473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physician support for a population-based pharmaceutical approach to cardiovascular prevention: not there yet.
    Huy C; Litaker D
    Prev Med; 2011 Jan; 52(1):18-9. PubMed ID: 21130110
    [No Abstract]   [Full Text] [Related]  

  • 17. Polypill remains the only panacea in sight for cardiovascular disease, trial organiser says.
    Hawkes N
    BMJ; 2012 Jul; 345():e4837. PubMed ID: 22807080
    [No Abstract]   [Full Text] [Related]  

  • 18. [The polypill as cardiovascular prophylactic: clinical trials].
    Sandli OK; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefits, challenges, and registerability of the polypill.
    Sleight P; Pouleur H; Zannad F
    Eur Heart J; 2006 Jul; 27(14):1651-6. PubMed ID: 16603580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.